D. Carmier

1.4k citations
23 papers · 868 · 2 hit papers · h-index 10

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Occupational and environmental lung diseases
    • Lung Cancer Treatments and Mutations
    • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Papers in

    • Cancer Immunotherapy and Biomarkers 4
    • Lung Cancer Research Studies 3
    • Lung Cancer Treatments and Mutations 4
    • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 2
    • Lung Cancer Diagnosis and Treatment 2

D. Carmier

22 papers receiving 846 citations

D. Carmier's Hit Papers

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer 2024 · 108 citations
1080+2+4Years since publication100200300

Peers

D. Carmier
Comparison fields: 5 of 41
  • Oncology 346
  • Pulmonary and Respiratory Medicine 402
  • Rheumatology 63
  • Genetics 15
  • Cancer Research 18
Replace S. Ferrari with:
S. Ferrari Italy
Keiichiro Uehara Japan
Ruth Salazar United States
Yuanxiang Guan China
Lilia Bardoscia Italy
Maria D. Begnami Brazil
Yuko Toyoda Japan
Susumu Joyama Japan
G. Fiorentini Italy
Tuğba Akın Telli Türkiye
D. Carmier relative to S. Ferrari Italy S. Ferrari's profile →
Citations per field
00.5×2×4×5.6×
S. Ferrari · 1×
Citations per year

Countries citing papers authored by D. Carmier

Since Specialization
Citations

This map shows the geographic impact of D. Carmier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Carmier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Carmier more than expected).

Fields of papers citing papers by D. Carmier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Carmier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Carmier. The network helps show where D. Carmier may publish in the future.

Co-authors

The 25 scholars most cited alongside D. Carmier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Carmier Line = papers co-authored together D. Carmier links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Hit paper breakdown →
2019364
2 2019149
3
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Hit paper breakdown →
2024108
4 201044
5 202039
6 201132
7 201830
8 201123
9 200820
10 201317
11 20189
12 20158
13 20228
14 20225
15 20172
16 20172
17 20222
18 20232
19 20131
20 20201

About D. Carmier

D. Carmier is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Rheumatology, Parasitology and Dermatology, having authored 23 papers that have together received 868 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Treatments and Mutations (4 papers), Systemic Lupus Erythematosus Research (3 papers), Lung Cancer Research Studies (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Lung Cancer Diagnosis and Treatment (2 papers), Dermatology and Skin Diseases (1 paper) and Systemic Sclerosis and Related Diseases (1 paper). The work is most often cited by research in Oncology (346 citations), Pulmonary and Respiratory Medicine (402 citations), Rheumatology (63 citations), Genetics (15 citations) and Cancer Research (18 citations). D. Carmier has collaborated with scholars based in France. Frequent co-authors include P. Diot, Élisabeth Diot, Sylvain Marchand-Adam, Éric Pichon, Théodora Bejan‐Angoulvant, Valérie Gounant, Emmanuelle Vermès, Marion Campana, Marion Ferreira and Franck Morin. Their work appears in journals such as Annals of Oncology, Clinical Infectious Diseases, Cancers, The Lancet Oncology and Journal of Clinical Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact